Nothing Special   »   [go: up one dir, main page]

Perry et al., 2024 - Google Patents

Insights into product and process related challenges of lentiviral vector bioprocessing

Perry et al., 2024

View PDF
Document ID
4298933308422423805
Author
Perry C
Mujahid N
Takeuchi Y
Rayat A
Publication year
Publication venue
Biotechnology and Bioengineering

External Links

Snippet

Lentiviral vectors (LVs) are used in advanced therapies to transduce recipient cells for long term gene expression for therapeutic benefit. The vector is commonly pseudotyped with alternative viral envelope proteins to improve tropism and is selected for enhanced …
Continue reading at analyticalsciencejournals.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Similar Documents

Publication Publication Date Title
Perry et al. Lentiviral vector bioprocessing
Martínez-Molina et al. Large-scale production of lentiviral vectors: current perspectives and challenges
De las Mercedes Segura et al. Downstream processing of oncoretroviral and lentiviral gene therapy vectors
Moreira et al. Advances in lentivirus purification
Manceur et al. Scalable lentiviral vector production using stable HEK293SF producer cell lines
Cribbs et al. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells
Perry et al. Insights into product and process related challenges of lentiviral vector bioprocessing
EP3377618B1 (en) Buffers for stabilization of lentiviral preparations
CN105980571A (en) Method for purifying enveloped viruses or viral vectors
US10273462B2 (en) Virus-based vector compositions useful for transducing eukaryotic cells
Williams et al. Lentiviral vector manufacturing process enhancement utilizing TFDF™ technology
Uchida et al. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders
Tinch et al. A scalable lentiviral vector production and purification method using mustang Q chromatography and tangential flow filtration
Sinn et al. Lentiviral vectors pseudotyped with filoviral glycoproteins
Boudeffa et al. Toward a scalable purification protocol of GaLV-TR-pseudotyped lentiviral vectors
KR20230024891A (en) Methods for making viral vectors
Satoh et al. Gene transduction in human monocyte-derived dendritic cells using lentiviral vectors
CN113166782A (en) Method for enhancing lentiviral vector production
Frenster et al. Lentiviral transduction of primary human glioblastoma cultures
CN101532031A (en) Non-integration slow virus vector system and preparation and application thereof
US11021700B2 (en) Method for purifying viral vectors
Rosales Gerpe et al. Optimized pre-clinical grade production of two novel lentiviral vector pseudotypes for lung gene delivery
Gödecke et al. Stable expression by lentiviral transduction of cells
JP2014528729A (en) Virus vector purification system
Nilsson Process development of lentiviral vector expression, purification and formulation for gene therapy applications